Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Trial Profile

Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Tipiracil/trifluridine (Primary)
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms RECOURSE
  • Sponsors Taiho Oncology
  • Most Recent Events

    • 05 Jun 2018 Results of pooled data from CheckMate 142, RECOURSE, and CALGB/SWOG 80405, were presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 06 Mar 2018 According to a Taiho Pharma Canada media release, the Health Canada approved LONSURF (trifluridine/tipiracil) for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with, or are not candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF biological agents, and, if RAS wild-type, anti-EGFR agents. The approval was based on results from this trial.
    • 20 Jan 2018 Results of a post-hoc analysis assessing the prognostic value of neutrophil-to-lymphocyte ratio on the clinical outcomes (n=782) presented at the 2018 Gastrointestinal Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top